The
data examined by GME predicted that by 2026, the Global Preclinical Imaging (In-Vivo) Market
would grow with a CAGR value of 6.2 percent. Preclinical
imaging in vivo is market expected to develop at a rapid pace in the near
future, due to factors such as the technology advances and a rise in the
incidence of chronic diseases like rheumatoid arthritis, neurological diseases,
cancer, and cardiovascular disease.
Browser the
Report @ https://www.globalmarketestimates.com/market-report/global-preclinical-imaging-in-vivo-market-3208
By
Modality (Optical Imaging,
PET, SPECT, CT, MRI, Ultrasound, Photoacoustic Imaging, Magnetic Particle
Imaging), By Reagent (Optical Imaging Reagents,
Contrast Agents, PET Tracers, SPECT Probes), By Region (North America, Asia
Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape,
Company Market Share Analysis & Competitor Analysis
Key Market Insights
· For
drug creation, preclinical imaging (In-Vivo) is used in live animal testing.
Preclinical imaging is also used to track patient reactions and look for
early signs of efficacy.
· Micro
Ultrasound played a major role in 2020 and is expected to rise at the highest
rate, owing to its wide variety of applications and effectiveness in conducting
research on small animal models.
· The
preclinical optical imaging reagents bagged the top market share during the
period of 2021 to 2026.
· FUJIFILM
Holdings Corporation, MR Solutions Ltd., Bruker Corporation, Trifoil Imaging,
Mediso Ltd, Aspect Imaging, LI-COR Biosciences, MILabs B.V., PerkinElmer, Inc.,
and Miltenyi Biotec GmbH are some major players competing in the global
preclinical imaging market.
Browse
the Report @ https://www.globalmarketestimates.com/market-report/global-preclinical-imaging-in-vivo-market-3208
Modality
Outlook (Revenue, USD Million, 2021-2026)
- Optical Imaging Systems
- Bioluminescence/Fluorescence Imaging Systems
- Standalone Fluorescence Imaging Systems
- Optical + X-Ray/Optical + CT
- Preclinical Nuclear Imaging Systems
- Micro-PET Systems
- Micro-SPECT Systems
- Trimodality (SPECT/PET/CT) Systems
- Micro-MRI Systems
- Micro-Ultrasound Systems
- Micro-CT Systems
- Preclinical Photoacoustic Imaging Systems
- Preclinical Magnetic Particle Imaging (MPI)
Systems
Reagent Outlook
(Revenue, USD Million, 2021-2026)
- Preclinical Optical Imaging Reagents
- Bioluminescent Imaging Reagents
- Fluorescent Imaging Reagents
- Preclinical Nuclear Imaging Reagents
- Preclinical PET Tracers
- Preclinical SPECT Probes
- Preclinical MRI Contrast Agents
- Gadolinium-based Preclinical MRI Contrast
Agents
- Iron-based Preclinical MRI Contrast Agents
- Manganese-based Preclinical MRI Contrast
Agents
- Preclinical Ultrasound Contrast Agents
- Preclinical CT Contrast Agents
- Iodine-based Preclinical CT Contrast Agents
- Barium-based Preclinical CT Contrast Agents
- Gold Nanoparticles
- Gastrografin-based Preclinical CT Contrast
Agents
Regional Outlook
(Revenue, USD Million, 2021-2026)
North America
- The
U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest
of Europe
Asia Pacific
- China
- India
- Japan
- South
Korea
- Australia
- Rest
of APAC
Central
& South America
- Brazil
- Argentina
- Rest
of CSA
Middle
East & Africa
- Saudi
Arabia
- UAE
- Rest
of MEA
Contact:
Tracy Simon
Email
address: tracy.simon@globalmarketestimates.com
Phone
Number: +16026667238
Website:
https://www.globalmarketestimates.com/
Check
our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php
No comments:
Post a Comment